ArticleJournal of contemporary brachytherapy2026
Magnetic resonance imaging-guided salvage high-dose-rate brachytherapy for local recurrence after prostatectomy and external beam radiotherapy.
Article in Journal of contemporary brachytherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the safety and efficacy of high-dose-rate (HDR) prostate brachytherapy (BT) in patients with local relapse after initial treatment with radical prostatectomy and salvage external beam radiation therapy (EBRT). Material and methods: Patients with local recurrence of prostate adenocarcinoma were retrospectively identified at a single-institution between 2015 and 2024. Recurrence was confirmed by imaging (MRI or choline PET) after prostatectomy and EBRT. Patients had no evidence of distant disease. A total HDR-BT dose of 17 Gy to 20 Gy was administered in two fractions. Results: Seventeen patients received salvage HDR-BT. The median follow-up time was 74 months (range, 6-100). Twelve patients (70.6%) received salvage-intent EBRT after surgery, while five (29.4%) had adjuvant EBRT. Three patients received androgen deprivation therapy (ADT) concurrently with EBRT in a mean ADT duration of 72 months (range, 6-126). The median time to PSA nadir after EBRT was 14 months. The median interval between EBRT and HDR-BT was 4 years (range, 1-14). After a median follow-up of six years from HDR-BT, 9 (52.9%) patients remained free of local recurrence, and 11 (64.7%) were recurrence-free in the treated region. In terms of toxicity, one patient experienced chronic grade 4 genitourinary toxicity requiring cystectomy, but no acute or late gastrointestinal toxicity was observed. At last follow-up, 15 patients (88.2%) were alive. Conclusions: In this long-term single-institution series, salvage HDR-BT demonstrates durable local control with acceptable toxicity in patients with local recurrence after prostatectomy and EBRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.